Mucosal vaccination against bacterial respiratory infections

Expert Review of Vaccines

Volumn 7, Issue 8, 2008, Pages 1257-1276

  Baumann, Ulrich ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Adjuvant; Bordetella pertussis; Haemophilus influenzae; Moraxella catarrhalis; Mucosa associated lymphoid tissue; Mucosal vaccination; Mycobacterium tuberculosis; Nasal vaccination; Oral vaccination; Pseudomonas aeroginosa; Respiratory infection

Indexed keywords

ADHESIN; BACTERIUM LYSATE; BCG VACCINE; CHITOSAN; CHOLERA TOXIN; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INFLUENZA VACCINE; MENINGITIS VACCINE; ORAL POLIOMYELITIS VACCINE; PERTUSSIS VACCINE; PNEUMOCOCCUS VACCINE; POLIOMYELITIS VACCINE; PSEUDOMONAS VACCINE; SALMONELLOSIS VACCINE;

BACTERIAL MENINGITIS; BACTERIAL PNEUMONIA; BORDETELLA PERTUSSIS; HAEMOPHILUS INFLUENZAE; HUMAN; INFLUENZA VACCINATION; LIPOSOMAL DELIVERY; MICROINJECTION; MORAXELLA CATARRHALIS; MYCOBACTERIUM TUBERCULOSIS; NEISSERIA MENINGITIDIS; NONHUMAN; PERTUSSIS; POLIOMYELITIS; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RESPIRATORY TRACT INFECTION; RESPIRATORY TRACT MUCOSA; REVIEW; SALMONELLOSIS; STREPTOCOCCUS PNEUMONIAE; TUBERCULOSIS; VACCINATION; VACCINE PRODUCTION;

ADMINISTRATION, INTRANASAL; ADMINISTRATION, ORAL; ADMINISTRATION, SUBLINGUAL; BACTERIAL INFECTIONS; BACTERIAL VACCINES; HUMANS; RESPIRATORY MUCOSA; RESPIRATORY TRACT INFECTIONS;

EID: 53849087185     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/14760584.7.8.1257     Document Type: Review

References (149)

1. CDC. Vaccine preventable deaths and the Global Immunization Vision and Strategy, 2006-2015. MMWR Morb. Mortal. Wkly Rep. 55(18), 511-515 (2006). •• Provides data on the global burden of infectious diseases and expresses the WHO strategy for vaccine development.
2. Christenson B, Lundbergh P, Hedlund J, Ortqvist A. Effects of a large-scale intervention with influenza and 23-valent pneumococcal vaccines in adults aged 65 years or older: a prospective study. Lancet 357(9261), 1008-1011 (2001).
3. CDC. Pneumococcal disease. In: Epidemiology and Prevention of Vaccine Preventable Diseases: The Pink Book. CDC (Ed.). GA, USA 257-270 (2007).
4. CDC. Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease - United States, 1998-2003. MMWR Morb. Mortal. Wkly Rep. 54(36), 893-897 (2005). • Describes the effects of herd immunity achieved by the antipneumococcal routine vaccination of children.
5. Singleton RJ, Hennessy TW, Bulkow LR et al. Invasive pneumococcal disease caused by nonvaccine serotypes among Alaska native children with high levels of 7-valent pneumococcal conjugate vaccine coverage. JAMA 297(16), 1784-1792 (2007). • Reports serotype replacement following introduction of antipneumococcal routine vaccination of children.
6. Maestro B, Sanz JM. Novel approaches to fight Streptococcus pneumoniae. Recent Patents Anti-Infect. Drug Disc. 2(3), 188-196 (2007).
7. Eskola J, Kilpi T, Palmu A et al. Efficacy of a pneumococcal conjugate vaccine against acute otitis media. N. Engl. J. Med. 344(6), 403-409 (2001).
8. Obonyo CO, Lau J. Efficacy of Haemophilus influenzae type b vaccination of children: a meta-analysis. Eur. J. Clin. Microbiol. Infect. Dis. 25(2), 90-97 (2006).
9. Pollabauer EM, Petermann R, Ehrlich HJ. Group C meningococcal polysaccharidetetanus toxoid conjugate vaccine: a meta-analysis of immunogenicity, safety and posology. Hum. Vaccin. 1(4), 131-139 (2005). • Comprehensive meta-analysis of clinical trials with a meningitus C vaccine.
10. CDC. Meningococcal disease. In: Epidemiology and Prevention of Vaccine Preventable Diseases: The Pink Book. CDC (Ed.), GA, USA 271-281 (2007)
11. Sierra GV, Campa HC, Varcacel NM et al. Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba. NIPH Ann. 14(2), 195-207 (1991).
12. Bjune G, Hoiby EA, Gronnesby JK et al. Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway. Lancet 338(8775), 1093-1096 (1991).
13. de Moraes JC, Perkins BA, Camargo MC et al. Protective efficacy of a serogroup B meningococcal vaccine in Sao Paulo, Brazil. Lancet 340(8827), 1074-1078 (1992).
14. Tappero JW, Lagos R, Ballesteros AM et al. Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines: a randomized controlled trial in Chile. JAMA 281(16), 1520-1527 (1999).
15. Yero D, Pajon R, Perez Y et al. Identification by genomic immunization of a pool of DNA vaccine candidates that confer protective immunity in mice against Neisseria meningitidis serogroup B. Vaccine 25(28), 5175-5188 (2007).
16. Bottero D, Gaillard ME, Fingermann M et al. Pulsed-field gel electrophoresis, pertactin, pertussis toxin S1 subunit polymorphisms, and surfaceome analysis of vaccine and clinical Bordetella pertussis strains. Clin. Vaccine Immunol. 14(11), 1490-1498 (2007).
17. CDC. Pertussis outbreak in an Amish community - Kent County, Delaware, September 2004-February 2005. MMWR Morb. Mortal. Wkly Rep. 55(30), 817-821 (2006).
18. Verhamme KM, De Coster W, De Roo L et al. Pathogens in early-onset and late-onset intensive care unit-acquired pneumonia. Infect. Control Hosp. Epidemiol. 28(4), 389-397 (2007).
19. Rello J, Rodriguez A, Torres A et al. Implications of COPD in patients admitted to the intensive care unit by community-acquired pneumonia. Eur. Respir. J. 27(6), 1210-1216 (2006).
20. Ratjen F. Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis. Curr. Opin. Pulm. Med. 12(6), 428-432 (2006).
21. Fajardo A, Martinez-Martin N, Mercadillo M et al. The neglected intrinsic resistome of bacterial pathogens. PLoS ONE 3(2), e1619 (2008).
22. Doring G, Meisner C, Stern M. A double-blind randomized placebo-controlled Phase III study of a Pseudomonas aeruginosa flagella vaccine in cystic fibrosis patients. Proc. Natl Acad. Sci. USA 104(26), 11020-11025 (2007). •• First randomized controlled clinical trial with an antipseudomonal vaccine in cystic fibrosis. Demonstrates that antipseudomonal vaccination can be effective in this patient group.
23. Lang AB, Rudeberg A, Schoni MH et al. Vaccination of cystic fibrosis patients against Pseudomonas aeruginosa reduces the proportion of patients infected and delays time to infection. Pediatr. Infect. Dis. J. 23(6), 504-510 (2004).
24. Trunz BB, Fine P, Dye C. Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: a meta-analysis and assessment of cost-effectiveness. Lancet 367(9517), 1173-1180 (2006). • Analyzes the huge amount of data on the clinical use of bacillus Calmette-Guerin (BCG) vaccination.
25. Rodrigues A, Schellenberg JA, Roth A et al. Revaccination with Bacillus Calmette-Guerin (BCG) vaccine does not reduce morbidity from malaria in African children. Trop. Med. Int. Health 12(2), 224-229 (2007).
26. Brennan MJ, Fruth U, Milstien J et al. Development of new tuberculosis vaccines: a global perspective on regulatory issues. PLoS Med. 4(8), e252 (2007).
27. Wiker HG, Mustafa T, Malen H, Riise AM. Vaccine approaches to prevent tuberculosis. Scand. J. Immunol. 64(3), 243-250 (2006).
28. Plebani A, Soresina A, Rondelli R et al. Clinical, immunological, and molecular analysis in a large cohort of patients with X-linked agammaglobulinemia: an Italian multicenter study. Clin. Immunol. 104(3), 221-230 (2002).
29. Hammarstrom L, Vorechovsky I, Webster D. Selective IgA deficiency (SIgAD) and common variable immunodeficiency (CVID). Clin. Exp. Immunol. 120(2), 225-231 (2000).
30. Carsetti R, Rosado MM, Donnanno S et al. The loss of IgM memory B cells correlates with clinical disease in common variable immunodeficiency. J. Allergy Clin. Immunol. 115(2), 412-417 (2005).
31. Merrill WW, Naegel GP, Olchowski JJ, Reynolds HY. Immunoglobulin G subclass proteins in serum and lavage fluid of normal subjects. Quantitation and comparison with immunoglobulins A and E. Am. Rev. Respir. Dis. 131(4), 584-587 (1985).
32. Baumann U, Gocke K, Gewecke B, Freihorst J, von Specht BU. Assessment of pulmonary antibodies with induced sputum and bronchoalveolar lavage induced by nasal vaccination against Pseudomonas aeruginosa: a clinical Phase I/II study. Respir. Res. 8, 57 (2007). • Demonstrates the formation of mucosal antibodies in human lower airways following nasal protein vaccination without the use of adjuvants.
33. Baumann U, Schmidt RE, Gessner JE. New insights into the pathophysiology and in vivo function of IgG Fc receptors through gene deletion studies. Arch. Immunol. Ther. Exp. (Warsz.) 51(6), 399-406 (2003).
34. Sjoholm AG, Jonsson G, Braconier JH, Sturfelt G, Truedsson L. Complement deficiency and disease: an update. Mol. Immunol. 43(1-2), 78-85 (2006).
35. Yoshida T, Usui A, Kusumi T et al. A quantitative analysis of cedar pollen-specific immunoglobulins in nasal lavage supported the local production of specific IgE, not of specific IgG. Microbiol. Immunol. 49(6), 529-534 (2005).
36. Bellanti JA, Zeligs BJ, Mendez-Inocencio J et al. Immunologic studies of specific mucosal and systemic immune responses in Mexican school children after booster aerosol or subcutaneous immunization with measles vaccine. Vaccine 22(9-10), 1214-1220 (2004).
37. Brandtzaeg P. Role of secretory antibodies in the defence against infections. Int. J. Med. Microbiol. 293(1), 3-15 (2003).
38. Malley R, Srivastava A, Lipsitch M et al. Antibody-independent, interleukin-17A-mediated, cross-serotype immunity to pneumococci in mice immunized intranasally with the cell wall polysaccharide. Infect. Immun. 74(4), 2187-2195 (2006). • Provides experimental data suggesting that host defense against extracellular bacterial pathogens can rely solely on a cellular response.
39. + T cells. Infect. Immun. 76(6), 2678-2684 (2008).
40. Kunkel EJ, Butcher EC. Plasma-cell homing. Nat. Rev. Immunol. 3(10), 822-829 (2003). • Summarizes the evidence of mechanisms of mucosal homing.
41. Brandtzaeg P, Johansen FE. Mucosal B cells: phenotypic characteristics, transcriptional regulation, and homing properties. Immunol. Rev. 206, 32-63 (2005).
42. Heier I, Malmstrom K, Pelkonen AS et al. Bronchial response pattern of antigen presenting cells and regulatory T cells in children below two years of age. Thorax 63(8), 703-709 (2008).
43. Quiding-Jabrink M, Nordstrom I, Granstrom G et al. Differential expression of tissue-specific adhesion molecules on human circulating antibody-forming cells after systemic, enteric, and nasal immunizations. A molecular basis for the compartmentalization of effector B cell responses. J. Clin. Invest. 99(6), 1281-1286 (1997). •• First study to demonstrate the differential expression of mucosal homing receptors following various mucosal and the systemic route in humans.
44. Yoshida M, Claypool SM, Wagner JS et al. Human neonatal Fc receptor mediates transport of IgG into luminal secretions for delivery of antigens to mucosal dendritic cells. Immunity 20(6), 769-783 (2004).
45. Brandtzaeg P, Halstensen TS, Kett K et al. Immunobiology and immunopathology of human gut mucosa: humoral immunity and intraepithelial lymphocytes. Gastroenterology 97(6), 1562-1584 (1989).
46. Debertin AS, Tschernig T, Tonjes H et al. Nasal-associated lymphoid tissue (NALT): frequency and localization in young children. Clin. Exp. Immunol. 134(3), 503-507 (2003).
47. Turesson I. Distribution of immunoglobulin-containing cells in human bone marrow and lymphoid tissues. Acta Med. Scand. 199(4), 293-304 (1976).
48. Gordon SB, Miller DE, Day RB et al. Pulmonary immunoglobulin responses to Streptococcus pneumoniae are altered but not reduced in human immunodeficiency virus-infected Malawian adults. J. Infect. Dis. 188(5), 666-670 (2003).
49. Mestecky J, Moldoveanu Z, Elson CO. Immune response versus mucosal tolerance to mucosally administered antigens. Vaccine 23(15), 1800-1803 (2005).
50. Oliveira ML, Areas AP, Ho PL. Intranasal vaccines for protection against respiratory and systemic bacterial infections. Expert Rev. Vaccines 6(3), 419-429 (2007).
51. Sullivan VJ, Mikszta JA, Laurent P, Huang J, Ford B. Noninvasive delivery technologies: respiratory delivery of vaccines. Expert Opin. Drug Deliv. 3(1), 87-95 (2006). • Reviews nasal delivery systems.
52. Belshe RB, Mendelman PM, Treanor J et al. The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children. N. Engl. J. Med. 338(20), 1405-1412 (1998).
53. Belshe RB, Edwards KM, Vesikari T et al. Live attenuated versus inactivated influenza vaccine in infants and young children. N. Engl. J. Med. 356(7), 685-696 (2007). •• Randomized clinical trial that shows the superiority of a nasal live vaccine versus a systemic vaccine in children.
54. Durrer P, Gluck U, Spyr C et al. Mucosal antibody response induced with a nasal virosome-based influenza vaccine. Vaccine 21(27-28), 4328-4334 (2003).
55. Mutsch M, Zhou W, Rhodes P et al. Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland. N. Engl. J. Med. 350(9), 896-903 (2004).
56. Arnold H, Bumann D, Felies M et al. Enhanced immunogenicity in the murine airway mucosa with an attenuated Salmonella live vaccine expressing OprF-OprI from Pseudomonas aeruginosa. Infect. Immun. 72(11), 6546-6553 (2004).
57. Song JH, Nguyen HH, Cuburu N et al. Sublingual vaccination with influenza virus protects mice against lethal viral infection. Proc. Natl Acad. Sci. USA 105(5), 1644-1649 (2008).
58. Giri PK, Verma I, Khuller GK. Protective efficacy of intranasal vaccination with Mycobacterium bovis BCG against airway Mycobacterium tuberculosis challenge in mice. J. Infect. 53(5), 350-356 (2006). • One of the few experimental studies on sublingual vaccination.
59. Mielcarek N, Debrie AS, Raze D et al. Live attenuated B. pertussis as a single-dose nasal vaccine against whooping cough. PLoS Pathog. 2(7), e65 (2006).
60. Locht C, Antoine R, Raze D et al. Bordetella pertussis from functional genomics to intranasal vaccination. Int. J. Med. Microbiol. 293(7-8), 583-588 (2004).
61. Oliveira ML, Areas AP, Campos IB et al. Induction of systemic and mucosal immune response and decrease in Streptococcus pneumoniae colonization by nasal inoculation of mice with recombinant lactic acid bacteria expressing pneumococcal surface antigen A. Microbes Infect. 8(4), 1016-1024 (2006). • Demonstrates the potential of nasal vaccination with recombinant live attenuated bacteria expressing heterologous antigens.
62. Huter V, Hensel A, Brand E, Lubitz W. Improved protection against lung colonization by Actinobacillus pleuropneumoniae ghosts: characterization of a genetically inactivated vaccine. J. Biotechnol. 83(1-2), 161-172 (2000).
63. Riedmann EM, Kyd JM, Cripps AW, Lubitz W. Bacterial ghosts as adjuvant particles. Expert Rev. Vaccines 6(2), 241-253 (2007).
64. van Roosmalen ML, Kanninga R, El Khattabi M et al. Mucosal vaccine delivery of antigens tightly bound to an adjuvant particle made from food-grade bacteria. Methods 38(2), 144-149 (2006).
65. Duc le H, Hong HA, Atkins HS et al. Immunization against anthrax using Bacillus subtilis spores expressing the anthrax protective antigen. Vaccine 25(2), 346-355 (2007). • Demonstrates the potential of spores expressing heterologous antigens.
66. Goonetilleke NP, McShane H, Hannan CM et al. Enhanced immunogenicity and protective efficacy against Mycobacterium tuberculosis of bacille Calmette-Guerin vaccine using mucosal administration and boosting with a recombinant modified vaccinia virus Ankara. J. Immunol. 171(3), 1602-1609 (2003).
67. Wang J, Thorson L, Stokes RW et al. Single mucosal, but not parenteral, immunization with recombinant adenoviral-based vaccine provides potent protection from pulmonary tuberculosis. J. Immunol. 173(10), 6357-6365 (2004).
68. Fujimura Y, Akisada T, Harada T, Haruma K. Uptake of microparticles into the epithelium of human nasopharyngeal lymphoid tissue. Med. Mol. Morphol. 39(4), 181-186 (2006).
69. de Jonge MI, Hamstra HJ, Jiskoot W et al. Intranasal immunisation of mice with liposomes containing recombinant meningococcal OpaB and OpaJ proteins. Vaccine 22(29-30), 4021-4028 (2004).
70. Kang ML, Jiang HL, Kang SG et al. Pluronic F127 enhances the effect as an adjuvant of chitosan microspheres in the intranasal delivery of Bordetella bronchiseptica antigens containing dermonecrotoxin. Vaccine 25(23), 4602-4610 (2007).
71. Baudner BC, Verhoef JC, Giuliani MM et al. Protective immune responses to meningococcal C conjugate vaccine after intranasal immunization of mice with the LTK63 mutant plus chitosan or trimethyl chitosan chloride as novel delivery platform. J. Drug Target 13(8-9), 489-498 (2005). • Compares different adjuvants for nasal vaccination.
72. Hou Y, Hu WG, Hirano T, Gu XX. A new intra-NALT route elicits mucosal and systemic immunity against Moraxella catarrhalis in a mouse challenge model. Vaccine 20(17-18), 2375-2381 (2002).
73. Larbig M, Mansouri E, Freihorst J et al. Safety and immunogenicity of an intranasal Pseudomonas aeruginosa hybrid outer membrane protein F-I vaccine in human volunteers. Vaccine 19(17-19), 2291-2297 (2001).
74. DiGiandomenico A, Rao J, Goldberg JB. Oral vaccination of BALB/c mice with Salmonella enterica serovar Typhimurium expressing Pseudomonas aeruginosa O antigen promotes increased survival in an acute fatal pneumonia model. Infect. Immun. 72(12), 7012-7021 (2004).
75. Toth A, Schodel F, Duchene M et al. Protection of immunosuppressed mice against translocation of Pseudomonas aeruginosa from the gut by oral immunization with recombinant Pseudomonas aeruginosa outer membrane protein I expressing Salmonella Dublin. Vaccine 12(13), 1215-1221 (1994).
76. Xin W, Wanda SY, Li Y et al. Analysis of Type II secretion of recombinant pneumococcal PspA and PspC in a Salmonella enterica serovar Typhimurium vaccine with regulated delayed antigen synthesis. Infect. Immun. 76(7), 3241-3254 (2008).
77. Cheminay C, Hensel M. Rational design of Salmonella recombinant vaccines. Int. J. Med. Microbiol. 298(1-2), 87-98 (2008).
78. Freytag LC, Clements JD. Mucosal adjuvants. Vaccine 23(15), 1804-1813 (2005).
79. Fraser CK, Diener KR, Brown MP, Hayball JD. Improving vaccines by incorporating immunological coadjuvants. Expert Rev. Vaccines 6(4), 559-578 (2007). •• Comprehensive review on adjuvants, including mucosal application.
80. Sabirov A, Metzger DW. Intranasal vaccination of neonatal mice with polysaccharide conjugate vaccine for protection against pneumococcal otitis media. Vaccine 24(27-28), 5584-5592 (2006).
81. Sabirov A, Metzger DW. Intranasal vaccination of infant mice induces protective immunity in the absence of nasal-associated lymphoid tissue. Vaccine 26(12), 1566-1576 (2008).
82. Lynch JM, Briles DE, Metzger DW. Increased protection against pneumococcal disease by mucosal administration of conjugate vaccine plus interleukin-12. Infect. Immun. 71(8), 4780-4788 (2003).
83. Wu HY, Nahm MH, Guo Y, Russell MW, Briles DE. Intranasal immunization of mice with PspA (pneumococcal surface protein A) can prevent intranasal carriage, pulmonary infection, and sepsis with Streptococcus pneumoniae. J. Infect. Dis. 175(4), 839-846 (1997). • One of the first studies to demonstrate superiority of nasal compared with systemic vaccination.
84. Tanaka N, Fukuyama S, Fukuiwa T et al. Intranasal immunization with phosphorylcholine induces antigen specific mucosal and systemic immune responses in mice. Vaccine 25(14), 2680-2687 (2007).
85. Hirano T, Jiao X, Chen Z, Van Waes C, Gu XX. Kinetics of mouse antibody and lymphocyte responses during intranasal vaccination with a lipooligosaccharide-based conjugate vaccine. Immunol. Lett. 107(2), 131-139 (2006).
86. Abe N, Kodama S, Hirano T, Eto M, Suzuki M. Nasal vaccination with CpG oligodeoxynucleotide induces protective immunity against non-typeable Haemophilus influenzae in the nasopharynx. Laryngoscope 116(3), 407-412 (2006).
87. Hotomi M, Ikeda Y, Suzumoto M et al. A recombinant P4 protein of Haemophilus influenzae induces specific immune responses biologically active against nasopharyngeal colonization in mice after intranasal immunization. Vaccine 23(10), 1294-1300 (2005).
88. Kodama S, Hirano T, Abe N, Suzuki M. Local application of CpG oligodeoxynucleotide enhances nontypeable Haemophilus influenzae-specific mucosal IgA responses in the middle ear. Acta Otolaryngol. 127(8), 809-815 (2007).
89. Mason KW, Zhu D, Scheuer CA et al. Reduction of nasal colonization of nontypeable Haemophilus influenzae following intranasal immunization with rLP4/rLP6/UspA2 proteins combined with aqueous formulation of RC529. Vaccine 22(25-26), 3449-3456 (2004).
90. Jiao X, Hirano T, Hou Y, Gu XX. Specific immune responses and enhancement of murine pulmonary clearance of Moraxella catarrhalis by intranasal immunization with a detoxified lipooligosaccharide conjugate vaccine. Infect. Immun. 70(11), 5982-5989 (2002).
91. Clancy RL, Cripps AW, Husband AJ, Buckley D. Specific immune response in the respiratory tract after administration of an oral polyvalent bacterial vaccine. Infect. Immun. 39(2), 491-496 (1983).
92. Tandon MK, Gebski V. A controlled trial of a killed Haemophilus influenzae vaccine for prevention of acute exacerbations of chronic bronchitis. Aust. NZ J. Med. 21(4), 427-432 (1991).
93. Steurer-Stey C, Lagler L, Straub DA, Steurer J, Bachmann LM. Oral purified bacterial extracts in acute respiratory tract infections in childhood: a systematic quantitative review. Eur. J. Pediatr. 166(4), 365-376 (2007).
94. Zhu D, Barniak V, Zhang Y, Green B, Zlotnick G. Intranasal immunization of mice with recombinant lipidated P2086 protein reduces nasal colonization of group B Neisseria meningitidis. Vaccine 24(26), 5420-5425 (2006).
95. Shoemaker DR, Saunders NB, Brandt BL et al. Intranasal delivery of group B meningococcal native outer membrane vesicle vaccine induces local mucosal and serum bactericidal antibody responses in rabbits. Infect. Immun. 73(8), 5031-5038 (2005).
96. Giuliani MM, Adu-Bobie J, Comanducci M et al. A universal vaccine for serogroup B meningococcus. Proc. Natl Acad. Sci. USA 103(29), 10834-10839 (2006).
97. Bowe F, Lavelle EC, McNeela EA et al. Mucosal vaccination against serogroup B meningococci: induction of bactericidal antibodies and cellular immunity following intranasal immunization with NadA of Neisseria meningitidis and mutants of Escherichia coli heat-labile enterotoxin. Infect. Immun. 72(7), 4052-4060 (2004).
98. Huo Z, Sinha R, McNeela EA et al. Induction of protective serum meningococcal bactericidal and diphtherianeutralizing antibodies and mucosal immunoglobulin A in volunteers by nasal insufflations of the Neisseria meningitidis serogroup C polysaccharide-CRM197 conjugate vaccine mixed with chitosan. Infect. Immun. 73(12), 8256-8265 (2005).
99. Alonso S, Willery E, Renauld-Mongenie G, Locht C. Production of nontypeable Haemophilus influenzae HtrA by recombinant Bordetella pertussis with the use of filamentous hemagglutinin as a carrier. Infect. Immun. 73(7), 4295-4301 (2005).
100. Lee SF, Halperin SA, Salloum DF, MacMillan A, Morris A. Mucosal immunization with a genetically engineered pertussis toxin S1 fragment-cholera toxin subunit B chimeric protein. Infect. Immun. 71(4), 2272-2275 (2003).
101. Hale C, Humphreys IR, Hussell T et al. Mucosal immunisation of murine neonates using whole cell and acellular pertussis vaccines. Vaccine 22(27-28), 3595-3602 (2004).
102. Berstad AK, Holst J, Froholm LO et al. A nasal whole-cell pertussis vaccine induces specific systemic and cross-reactive mucosal antibody responses in human volunteers. J. Med. Microbiol. 49(2), 157-163 (2000).
103. Priebe GP, Meluleni GJ, Coleman FT, Goldberg JB, Pier GB. Protection against fatal Pseudomonas aeruginosa pneumonia in mice after nasal immunization with a live, attenuated aroA deletion mutant. Infect. Immun. 71(3), 1453-1461 (2003).
104. Gocke K, Baumann U, Hagemann H et al. Mucosal vaccination with a recombinant OprF-I vaccine of Pseudomonas aeruginosa in healthy volunteers: comparison of a systemic vs. a mucosal booster schedule. FEMS Immunol. Med. Microbiol. 37(2-3), 167-171 (2003).
105. Kaufmann SH. Recent findings in immunology give tuberculosis vaccines a new boost. Trends Immunol. 26(12), 660-667 (2005).
106. Tjarnlund A, Rodriguez A, Cardona PJ et al. Polymeric IgR knockout mice are more susceptible to mycobacterial infections in the respiratory tract than wild-type mice. Int. Immunol. 18(5), 807-816 (2006).
107. Hamasur B, Haile M, Pawlowski A et al. A mycobacterial lipoarabinomannan specific monoclonal antibody and its F(ab′) fragment prolong survival of mice infected with Mycobacterium tuberculosis. Clin. Exp. Immunol. 138(1), 30-38 (2004).
108. Kallenius G, Pawlowski A, Brandtzaeg P, Svenson S. Should a new tuberculosis vaccine be administered intranasally? Tuberculosis (Edinb.) 87(4), 257-266 (2007).
109. Chen L, Wang J, Zganiacz A, Xing Z. Single intranasal mucosal Mycobacterium bovis BCG vaccination confers improved protection compared with subcutaneous vaccination against pulmonary tuberculosis. Infect. Immun. 72(1), 238-246 (2004).
110. + T cells to nasal killed-bacillus Calmette-Guerin in mice. Vaccine 24(17), 3591-3598 (2006).
111. Haile M, Hamasur B, Jaxmar T et al. Nasal boost with adjuvanted heat-killed BCG or arabinomannan-protein conjugate improves primary BCG-induced protection in C57BL/6 mice. Tuberculosis (Edinb.) 85(1-2), 107-114 (2005).
112. Santosuosso M, McCormick S, Zhang X, Zganiacz A, Xing Z. Intranasal boosting with an adenovirus-vectored vaccine markedly enhances protection by parenteral Mycobacterium bovis BCG immunization against pulmonary tuberculosis. Infect. Immun. 74(8), 4634-4643 (2006).
113. Dietrich J, Andersen C, Rappuoli R et al. Mucosal administration of Ag85B-ESAT-6 protects against infection with Mycobacterium tuberculosis and boosts prior bacillus Calmette-Guerin immunity. J. Immunol. 177(9), 6353-6360 (2006). • One of a series of studies demonstrating improved protection with a nasal booster following BCG primary vaccination.
114. Rudin A, Riise GC, Holmgren J. Antibody responses in the lower respiratory tract and male urogenital tract in humans after nasal and oral vaccination with cholera toxin B subunit. Infect. Immun. 67(6), 2884-2890 (1999). •• One of the few studies systematically assessing mucosal antibody induction following nasal and oral immunization.
115. Ebensen T, Schulze K, Riese P, Morr M, Guzman CA. The bacterial second messenger cdiGMP exhibits promising activity as a mucosal adjuvant. Clin. Vaccine Immunol. 14(8), 952-958 (2007).
116. Hall MA, Stroop SD, Hu MC et al. Intranasal immunization with multivalent group A streptococcal vaccines protects mice against intranasal challenge infections. Infect. Immun. 72(5), 2507-2512 (2004).
117. Becker PD, Bertot GM, Souss D et al. Intranasal vaccination with recombinant outer membrane protein CD and adamantylamide dipeptide as the mucosal adjuvant enhances pulmonary clearance of Moraxella catarrhalis in an experimental murine model. Infect. Immun. 75(4), 1778-1784 (2007).
118. Ebensen T, Link C, Riese P et al. A pegylated derivative of a-galactosylceramide exhibits improved biological properties. J. Immunol. 179(4), 2065-2073 (2007).
119. Ebensen T, Schulze K, Riese P et al. The bacterial second messenger cyclic diGMP exhibits potent adjuvant properties. Vaccine 25(8), 1464-1469 (2007).
120. Link C, Gavioli R, Ebensen T et al. The Toll-like receptor ligand MALP-2 stimulates dendritic cell maturation and modulates proteasome composition and activity. Eur. J. Immunol. 34(3), 899-907 (2004).
121. Larbig M, Mansouri E, Freihorst J et al. Safety and immunogenicity of an intranasal Pseudomonas aeruginosa hybrid outer membrane protein F-I vaccine in human volunteers. Vaccine 19(17-19), 2291-2297 (2001).
122. Audouy SA, van Roosmalen ML, Neef J et al. Lactococcus lactis GEM particles displaying pneumococcal antigens induce local and systemic immune responses following intranasal immunization. Vaccine 24(26), 5434-5441 (2006).
123. Malley R, Lipsitch M, Stack A et al. Intranasal immunization with killed unencapsulated whole cells prevents colonization and invasive disease by capsulated pneumococci. Infect. Immun. 69(8), 4870-4873 (2001).
124. Andersen CS, Dietrich J, Agger EM et al. The combined CTA1-DD/ISCOMs vector is an effective intranasal adjuvant for boosting prior Mycobacterium bovis BCG immunity to Mycobacterium tuberculosis. Infect. Immun. 75(1), 408-416 (2007).
125. Nawar HF, Arce S, Russell MW, Connell TD. Mutants of type II heat-labile enterotoxin LT-IIa with altered ganglioside-binding activities and diminished toxicity are potent mucosal adjuvants. Infect. Immun. 75(2), 621-633 (2007).
126. Lynch JM, Briles DE, Metzger DW. Increased protection against pneumococcal disease by mucosal administration of conjugate vaccine plus interleukin-12. Infect. Immun. 71(8), 4780-4788 (2003).
127. Wang J, Thorson L, Stokes RW et al. Single mucosal, but not parenteral, immunization with recombinant adenoviral-based vaccine provides potent protection from pulmonary tuberculosis. J. Immunol. 173(10), 6357-6365 (2004).
128. Audouy SA, van Selm S, van Roosmalen ML et al. Development of lactococcal GEM-based pneumococcal vaccines. Vaccine 25(13), 2497-2506 (2007).
129. Briles DE, Ades E, Paton JC et al. Intranasal immunization of mice with a mixture of the pneumococcal proteins PsaA and PspA is highly protective against nasopharyngeal carriage of Streptococcus pneumoniae. Infect. Immun. 68(2), 796-800 (2000).
130. Areas AP, Oliveira ML, Miyaji EN et al. Expression and characterization of cholera toxin B-pneumococcal surface adhesin A fusion protein in Escherichia coli: ability of CTB-PsaA to induce humoral immune response in mice. Biochem. Biophys. Res. Commun. 321(1), 192-196 (2004).
131. Pimenta FC, Miyaji EN, Areas AP et al. Intranasal immunization with the cholera toxin B subunit-pneumococcal surface antigen A fusion protein induces protection against colonization with Streptococcus pneumoniae and has negligible impact on the nasopharyngeal and oral microbiota of mice. Infect. Immun. 74(8), 4939-4944 (2006).
132. Seo JY, Seong SY, Ahn BY et al. Cross-protective immunity of mice induced by oral immunization with pneumococcal surface adhesin a encapsulated in microspheres. Infect. Immun. 70(3), 1143-1149 (2002).
133. Baudner BC, Balland O, Giuliani MM et al. Enhancement of protective efficacy following intranasal immunization with vaccine plus a nontoxic LTK63 mutant delivered with nanoparticles. Infect. Immun. 70(9), 4785-4790 (2002).
134. Isaka M, Komiya T, Takahashi M et al. Recombinant cholera toxin B subunit (rCTB) as a mucosal adjuvant enhances induction of diphtheria and tetanus antitoxin antibodies in mice by intranasal administration with diphtheria-pertussis-tetanus (DPT) combination vaccine. Vaccine 22(23-24), 3061-3068 (2004).
135. Jabbal-Gill I, Fisher AN, Rappuoli R, Davis SS, Illum L. Stimulation of mucosal and systemic antibody responses against Bordetella pertussis filamentous haemagglutinin and recombinant pertussis toxin after nasal administration with chitosan in mice. Vaccine 16(20), 2039-2046 (1998).
136. Walker MJ, Rohde M, Timmis KN, Guzman CA. Specific lung mucosal and systemic immune responses after oral immunization of mice with Salmonella typhimurium aroA, Salmonella typhi Ty21a, and invasive Escherichia coli expressing recombinant pertussis toxin S1 subunit. Infect. Immun. 60(10), 4260-4268 (1992).
137. Zuercher AW, Horn MP, Que JU et al. Antibody responses induced by long-term vaccination with an octovalent conjugate Pseudomonas aeruginosa vaccine in children with cystic fibrosis. FEMS Immunol. Med. Microbiol. 47(2), 302-308 (2006).
138. Thomas LD, Kyd JM, Bastin DA, Dunkley ML, Cripps AW. Immunisation with non-integral OMPs promotes pulmonary clearance of Pseudomonas aeruginosa. FEMS Immunol. Med. Microbiol. 37(2-3), 155-160 (2003).
139. Buret A, Dunkley ML, Pang G, Clancy RL, Cripps AW. Pulmonary immunity to Pseudomonas aeruginosa in intestinally immunized rats roles of alveolar macrophages, tumor necrosis factor a, and interleukin-1 a. Infect. Immun. 62(12), 5335-5343 (1994).
140. Abraham E. Intranasal immunization with bacterial polysaccharide containing liposomes enhances antigen-specific pulmonary secretory antibody response. Vaccine 10(7), 461-468 (1992).
141. Stephenson I, Zambon MC, Rudin A et al. Phase I evaluation of intranasal trivalent inactivated influenza vaccine with nontoxigenic Escherichia coli enterotoxin and novel biovector as mucosal adjuvants, using adult volunteers. J. Virol. 80(10), 4962-4970 (2006).
142. Halperin SA, Smith B, Clarke K et al. Phase I, randomized, controlled trial to study the reactogenicity and immunogenicity of a nasal, inactivated trivalent influenza virus vaccine in healthy adults. Hum. Vaccin. 1(1), 37-42 (2005).
143. Langley JM, Halperin SA, McNeil S et al. Safety and immunogenicity of a proteosome-trivalent inactivated influenza vaccine, given nasally to healthy adults. Vaccine 24(10), 1601-1608 (2006).
144. Treanor J, Nolan C, O'Brien D et al. Intranasal administration of a proteosome-influenza vaccine is well-tolerated and induces serum and nasal secretion influenza antibodies in healthy human subjects. Vaccine 24(3), 254-262 (2006).
145. Fries LF, Montemarano AD, Mallett CP et al. Safety and immunogenicity of a proteosome-Shigella flexneri 2a lipopolysaccharide vaccine administered intranasally to healthy adults. Infect. Immun. 69(7), 4545-4553 (2001).
146. Van Kampen KR, Shi Z, Gao P et al. Safety and immunogenicity of adenovirus-vectored nasal and epicutaneous influenza vaccines in humans. Vaccine 23(8), 1029-1036 (2005).
147. McNeela EA, Jabbal-Gill I, Illum L et al. Intranasal immunization with genetically detoxified diphtheria toxin induces T cell responses in humans: enhancement of Th2 responses and toxin-neutralizing antibodies by formulation with chitosan. Vaccine 22(8), 909-914 (2004).
148. WHO. 2004 global immunization data www.who.int/immunization_monitoring/ data/globalimmunizationdata.pdf
149. WHO. 2008. Global Tuberculosis Control 2008. Surveillance, Planning, Financing (WHO, Geneva, 2008) www.who.int